Hospital
Anderson Regional Medical Center
Anderson Regional Medical Center was paid $32.50M by Medicaid between Jan 2018 and Dec 2024, across 335 billing codes. Its largest line is 99285, emergency room visit (most serious) — 16% of everything it billed.
33Billing provider infoANDERSON REGIONAL MEDICAL CENTER
MERIDIAN, MS 39301
MERIDIAN, MS 39301
33aNPI1649226952assigned 05/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.50M
24GClaims1,069,041
24DCodes billed335
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#15 of 77
Median peer was paid$8.23M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 128,733 | $4.57M | |
| 2019 | 147,594 | $5.26M | |
| 2020 | 136,451 | $4.02M | |
| 2021 | 174,694 | $5.01M | |
| 2022 | 193,101 | $5.18M | |
| 2023 | 167,776 | $4.83M | |
| 2024incomplete | 120,692 | $3.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 24,321 | 19,785 | $5.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 23,636 | 20,160 | $4.41M |
| G0378 | Hospital observation service, per hour | 8.8% | 7,019 | 5,685 | $2.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.6% | 17,676 | 15,355 | $2.47M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 13,910 | 10,203 | $1.10M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 10,810 | 6,924 | $891K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.6% | 23,431 | 15,920 | $830K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.4% | 8,576 | 3,930 | $776K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 4,789 | 4,111 | $709K |
| 71045 | Radiologic examination, chest; single view | 2.1% | 19,346 | 15,400 | $684K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 7,733 | 4,295 | $581K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 18,032 | 4,154 | $509K |
323 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 9,077 | $441K |
| 86900 | 1.2% | 6,794 | $379K | |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 10,186 | $377K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 8,873 | $364K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.0% | 11,850 | $339K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 18,095 | $338K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 20,442 | $334K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 14,545 | $329K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,955 | $311K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,596 | $305K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 11,115 | $284K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 62,716 | $284K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 21,445 | $255K |
| 80053 | Comprehensive metabolic panel | <1% | 39,315 | $250K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,852 | $250K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,576 | $244K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,283 | $241K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 4,172 | $224K |
| 59025 | Fetal non-stress test | <1% | 1,744 | $184K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,275 | $177K |
| 86850 | <1% | 6,153 | $160K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 8,207 | $155K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,751 | $151K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,460 | $146K |
| 74018 | <1% | 3,401 | $137K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,640 | $137K |
| 36415 | Collection of venous blood by venipuncture | <1% | 67,590 | $134K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,901 | $134K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 767 | $130K |
| 83880 | <1% | 5,923 | $120K | |
| 87070 | <1% | 16,834 | $116K | |
| 86901 | <1% | 6,798 | $114K | |
| 84484 | <1% | 16,439 | $111K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,399 | $95K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 52 | $92K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 996 | $82K |
| 74021 | <1% | 1,561 | $81K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 903 | $80K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,088 | $76K |
| 36430 | <1% | 736 | $74K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,011 | $73K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,391 | $73K |
| 73630 | <1% | 1,796 | $68K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,247 | $67K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,685 | $66K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,877 | $65K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 1,573 | $65K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 286 | $65K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 973 | $64K |
| 87088 | <1% | 11,558 | $64K | |
| 81001 | <1% | 31,449 | $63K | |
| 73560 | <1% | 1,805 | $63K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,032 | $63K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,228 | $61K |
| 97161 | <1% | 1,763 | $58K | |
| 96367 | <1% | 2,005 | $58K | |
| 77336 | <1% | 1,022 | $57K | |
| 80061 | Lipid panel | <1% | 7,547 | $57K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,503 | $55K |
| 83735 | <1% | 16,673 | $54K | |
| 87040 | <1% | 9,577 | $54K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,392 | $54K |
| 76801 | <1% | 761 | $52K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,386 | $50K |
| 73030 | <1% | 1,435 | $50K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 74 | $47K |
| 86920 | <1% | 815 | $46K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 607 | $45K |
| 81025 | <1% | 7,606 | $44K | |
| 76775 | <1% | 1,308 | $44K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 601 | $44K |
| 87186 | <1% | 6,936 | $42K | |
| 87077 | <1% | 7,051 | $40K | |
| 87807 | <1% | 3,721 | $40K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,669 | $39K |
| 86780 | <1% | 3,888 | $39K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 235 | $38K |
| 73610 | <1% | 892 | $38K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,647 | $35K |
| 83690 | <1% | 7,806 | $34K | |
| 84702 | <1% | 3,007 | $33K | |
| 93970 | <1% | 516 | $31K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 73 | $31K |
| 73502 | <1% | 1,026 | $31K | |
| 83605 | <1% | 4,698 | $29K | |
| 77300 | <1% | 276 | $29K | |
| 77386 | <1% | 209 | $28K | |
| 83655 | <1% | 2,304 | $25K | |
| 82607 | <1% | 3,302 | $25K | |
| 86762 | <1% | 2,303 | $25K | |
| 93971 | <1% | 710 | $25K | |
| 99490 | Ccm add 20min | <1% | 1,648 | $23K |
| 72110 | <1% | 400 | $23K | |
| 85610 | <1% | 9,742 | $22K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 721 | $21K |
| 87340 | <1% | 2,674 | $20K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 893 | $20K |
| 72100 | <1% | 426 | $19K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 533 | $19K |
| 73130 | <1% | 472 | $19K | |
| 85379 | <1% | 3,719 | $19K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,250 | $19K |
| 85730 | <1% | 5,386 | $19K | |
| 92523 | <1% | 118 | $18K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 624 | $17K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 624 | $17K |
| 82553 | <1% | 2,435 | $17K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 262 | $17K |
| 84439 | <1% | 3,220 | $16K | |
| 95811 | <1% | 36 | $16K | |
| 70486 | <1% | 281 | $16K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 47 | $15K |
| 82728 | <1% | 1,850 | $14K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 214 | $14K |
| 97162 | <1% | 463 | $14K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 186 | $13K |
| 82746 | <1% | 1,689 | $13K | |
| 93458 | <1% | 15 | $13K | |
| 82550 | <1% | 2,931 | $13K | |
| 43235 | <1% | 59 | $12K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 411 | $12K |
| 43450 | <1% | 153 | $12K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 26 | $12K |
| 86140 | <1% | 3,887 | $12K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 40 | $12K |
| 82150 | <1% | 2,780 | $11K | |
| 84703 | <1% | 2,272 | $11K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 59 | $11K |
| 77334 | <1% | 61 | $11K | |
| 87634 | <1% | 179 | $11K | |
| 88720 | <1% | 2,443 | $11K | |
| 82565 | <1% | 3,351 | $10K | |
| 97116 | <1% | 943 | $10K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 177 | $10K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 160 | $10K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 162 | $9K |
| 80076 | <1% | 2,024 | $9K | |
| 86003 | <1% | 198 | $9K | |
| 84152 | <1% | 881 | $8K | |
| 76641 | <1% | 168 | $8K | |
| 97014 | <1% | 786 | $8K | |
| 82248 | <1% | 1,952 | $8K | |
| 97165 | <1% | 284 | $7K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,661 | $7K |
| 76770 | <1% | 190 | $7K | |
| 82947 | <1% | 2,403 | $7K | |
| 82950 | <1% | 1,869 | $7K | |
| 85651 | <1% | 3,358 | $7K | |
| 73110 | <1% | 167 | $7K | |
| 72131 | <1% | 155 | $6K | |
| 77338 | <1% | 45 | $6K | |
| 96415 | <1% | 65 | $6K | |
| 85018 | <1% | 3,185 | $6K | |
| 83550 | <1% | 1,313 | $5K | |
| 80074 | <1% | 218 | $5K | |
| 72170 | <1% | 97 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 373 | $5K |
| 73590 | <1% | 144 | $5K | |
| 84146 | <1% | 385 | $4K | |
| 82140 | <1% | 554 | $4K | |
| 88312 | <1% | 206 | $4K | |
| 94060 | <1% | 61 | $4K | |
| 81003 | <1% | 2,906 | $3K | |
| 85660 | <1% | 735 | $3K | |
| 73090 | <1% | 81 | $3K | |
| 86769 | <1% | 153 | $3K | |
| 96401 | <1% | 88 | $3K | |
| 84480 | <1% | 318 | $3K | |
| 84550 | <1% | 1,196 | $3K | |
| 86038 | <1% | 430 | $3K | |
| 90686 | <1% | 308 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 36 | $3K |
| 72141 | <1% | 31 | $3K | |
| 82570 | <1% | 1,016 | $2K | |
| 82803 | <1% | 187 | $2K | |
| 76536 | <1% | 39 | $2K | |
| 73070 | <1% | 62 | $2K | |
| 85014 | <1% | 1,428 | $2K | |
| 93880 | <1% | 58 | $2K | |
| 87150 | <1% | 110 | $2K | |
| 82043 | <1% | 883 | $2K | |
| 87081 | <1% | 384 | $2K | |
| 73562 | <1% | 42 | $2K | |
| 82247 | <1% | 548 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,891 | $2K |
| 85027 | <1% | 496 | $2K | |
| 88300 | <1% | 93 | $2K | |
| 80069 | <1% | 350 | $1K | |
| 72040 | <1% | 32 | $1K | |
| 80305 | <1% | 197 | $1K | |
| 84132 | <1% | 478 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,125 | $1K |
| 86431 | <1% | 435 | $1K | |
| 86235 | <1% | 65 | $1K | |
| J3490 | Unclassified drugs | <1% | 8,570 | $1K |
| 72050 | <1% | 15 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,524 | $981.38 |
| 86200 | <1% | 150 | $968.16 | |
| 73551 | <1% | 27 | $949.08 | |
| 75635 | <1% | 14 | $890.04 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 16 | $883.80 |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $879.87 |
| 82785 | <1% | 76 | $872.13 | |
| 83615 | <1% | 272 | $858.11 | |
| 72070 | <1% | 17 | $782.01 | |
| 82951 | <1% | 77 | $776.94 | |
| 76857 | <1% | 16 | $767.38 | |
| 87428 | <1% | 17 | $731.91 | |
| 90756 | <1% | 66 | $695.96 | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 46 | $683.20 |
| 90662 | <1% | 120 | $662.04 | |
| 73620 | <1% | 19 | $656.35 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,832 | $653.39 |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 60 | $617.72 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,974 | $608.79 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,328 | $608.73 |
| 86480 | <1% | 14 | $607.58 | |
| 73120 | <1% | 12 | $594.02 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 31 | $574.71 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,353 | $561.84 |
| 83540 | <1% | 184 | $520.92 | |
| 85007 | <1% | 259 | $507.24 | |
| 87046 | <1% | 57 | $487.46 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,082 | $483.87 |
| 94727 | <1% | 29 | $436.28 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 441 | $420.02 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 37 | $405.42 |
| J2704 | Injection, propofol, 10 mg | <1% | 10,709 | $391.91 |
| 93923 | <1% | 12 | $389.07 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 28 | $387.33 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,134 | $366.12 |
| 83970 | <1% | 49 | $334.42 | |
| 86225 | <1% | 58 | $322.37 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,069 | $321.85 |
| 87045 | <1% | 45 | $319.56 | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 71 | $315.08 |
| 84481 | <1% | 46 | $304.93 | |
| 88342 | <1% | 20 | $253.10 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 423 | $247.60 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 754 | $242.80 |
| 86336 | <1% | 19 | $242.44 | |
| 84156 | <1% | 115 | $241.34 | |
| 82677 | <1% | 19 | $224.02 | |
| 85046 | <1% | 64 | $200.55 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,383 | $200.00 |
| G0008 | Administration of influenza virus vaccine | <1% | 529 | $199.60 |
| 85652 | <1% | 140 | $190.51 | |
| 86160 | <1% | 34 | $187.59 | |
| 80177 | <1% | 17 | $179.28 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 665 | $171.07 |
| 82105 | <1% | 33 | $168.82 | |
| 51702 | <1% | 16 | $163.98 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,875 | $161.51 |
| 84153 | <1% | 44 | $133.56 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 357 | $128.30 |
| 84100 | <1% | 77 | $125.86 | |
| 87205 | <1% | 38 | $118.65 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,935 | $111.23 |
| 84436 | <1% | 13 | $100.50 | |
| 82010 | <1% | 14 | $90.89 | |
| 86039 | <1% | 26 | $90.46 | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 13 | $84.32 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,912 | $81.98 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,950 | $79.40 |
| C1769 | Guide wire | <1% | 1,858 | $76.76 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,538 | $73.90 |
| 81050 | <1% | 49 | $62.35 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,091 | $40.49 |
| 96376 | <1% | 5,819 | $38.86 | |
| 87210 | <1% | 12 | $36.73 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,400 | $33.69 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 45 | $28.50 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,230 | $26.98 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 878 | $25.64 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,334 | $22.62 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,366 | $22.35 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 843 | $19.50 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 308 | $19.19 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,702 | $17.82 |
| J1815 | Injection, insulin, per 5 units | <1% | 5,069 | $17.46 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 149 | $8.67 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 178 | $6.78 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,416 | $6.54 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 798 | $5.85 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 66 | $5.32 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 353 | $5.28 |
| 90694 | <1% | 215 | $4.40 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 154 | $2.31 |
| 90715 | 0% | 233 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 133 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 48 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 142 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 384 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 58 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 15 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 576 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 33 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 144 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 432 | $0.00 |
| C1729 | Catheter, drainage | 0% | 36 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 123 | $0.00 |
| 94729 | 0% | 46 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 45 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 36 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 15 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 36 | $0.00 |
| 84145 | 0% | 13 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 19 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,983 | $0.00 |
| 94760 | 0% | 495 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 33 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 344 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 265 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 103 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 325 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 49 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 40 | $0.00 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 56 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 246 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 23 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 62 | $0.00 |
| 77417 | 0% | 103 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP / CLO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.